CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer

Table 1

Association of CLDN4 expression levels with clinical factors in ovarian cancer patients.

Characteristic	Low expression of CLDN4	High expression of CLDN4
	189	190
Age, (%)			1.000
≤60	104 (27.4%)	104 (27.4%)
>60	85 (22.4%)	86 (22.7%)
FIGO stage, (%)			0.203
Stage I	0 (0%)	1 (0.3%)
Stage II	14 (3.7%)	9 (2.4%)
Stage III	150 (39.9%)	145 (38.6%)
Stage IV	23 (6.1%)	34 (9%)
Histologic grade, (%)			0.269
G1	1 (0.3%)	0 (0%)
G2	19 (5.1%)	26 (7%)
G3	165 (44.7%)	157 (42.5%)
G4	0 (0%)	1 (0.3%)
Lymphatic invasion, (%)			0.817
No	23 (15.4%)	25 (16.8%)
Yes	52 (34.9%)	49 (32.9%)
Age, median (IQR)	59 (50, 69)	58.5 (52, 67)	0.786